BC
ACAD icon

Boxer Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Boxer Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,263,930
Closed -$20.7M – 72
2022
Q3 		$20.7M Hold
1,263,930
– – 1.16% 31
2022
Q2 		$17.8M Hold
1,263,930
– – 1.13% 31
2022
Q1 		$30.6M Buy
1,263,930
+1,078,930
+583% +$26.1M 1.57% 21
2021
Q4 		$4.32M Buy
+185,000
New +$3.72M 0.17% 60
2020
Q4 		– Sell
-370,000
Closed -$15.3M – 78
2020
Q3 		$15.3M Hold
370,000
– – 0.53% 43
2020
Q2 		$17.9M Hold
370,000
– – 0.79% 34
2020
Q1 		$15.6M Buy
+370,000
New +$15.2M 1.07% 29

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Boxer Capital's ACAD Position: Q4 2022 in Review

Boxer Capital sold out of Acadia Pharmaceuticals (ACAD) in Q4 2022, closing a stake of 1,263,930 shares — an estimated $20.7M sold.

Boxer Capital first reported a position in ACAD in Q1 2020 and held it in 7 quarters. The position peaked at $30.6M in Q1 2022. 227 funds tracked by Wall St. Rank hold ACAD as of Q4 2022.

  • Boxer Capital reported no remaining Acadia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Boxer Capital sold 1,263,930 Acadia Pharmaceuticals shares in Q4 2022, an estimated $20.7M.
  • Boxer Capital first reported a position in Acadia Pharmaceuticals in Q1 2020 and held it in 7 quarters.
  • Boxer Capital's Acadia Pharmaceuticals position peaked at $30.6M in Q1 2022.
  • 227 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2022.

Based on Boxer Capital's 13F filing for Q4 2022, filed 14 Feb 2023.